Van der Galien HT, Kooistra HA, Veeger NJGM, et al. Outcome of a 10-year population-based cohort of diffuse large B-cell lymphoma patients in the first-line, refractory and relapsed setting: ‘real world’ data identify subgroups in need of new therapies. EHA 2018; poster PF287.
Obinutuzumab- versus rituximab-immunochemotherapie bij eerder onbehandeld iNHL
okt 2023 | Immuuntherapie, Lymfoom